Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CPS1 | P31327 | 7/20 | 0.38 |
| ▸ | FPR1 | P21462 | 8/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 6/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19559531 | 1.00 | HCRTR1 (0.38) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL19559459 | 0.84 | PDE4A (0.50) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL18117769 | 0.84 | PDE4A (0.50) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL19559422 | 0.82 | HCRTR1 (0.38) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL19559537 | 0.82 | HCRTR1 (0.38) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL19559458 | 0.80 | FPR1 (0.54) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL19559542 | 0.80 | SMN1; SMN2 (0.42) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL18117771 | 0.80 | FPR1 (0.54) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL19559464 | 0.79 | SMN1; SMN2 (0.51) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 | |
| SCHEMBL20041907 | 0.79 | SMN1; SMN2 (0.41) | HCRTR1HCRTR2CPS1FPR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305763-A1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |